vTv Therapeutics Priced, Nasdaq: VTVT

Biotech developing treatments for Alzheimer's disease and type 2 diabetes.

Industry: Health Care

Latest Trade: $4.65 0.00 (0.0%)

First Day Return: -27.4%

Return from IPO: -69.0%

Industry: Health Care

We are a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. We have a powerful pipeline of clinical drug candidates, led by our programs for the treatment of AD and type 2 diabetes. Our drug candidate for the treatment of AD, azeliragon, is an orally administered, small molecule antagonist targeting RAGE, and we have commenced patient enrollment in the STEADFAST Study under an FDA-agreed SPA. Our type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective GKA, for which we are currently enrolling patients in the AGATA Study, and TTP273, an orally administered, non-peptide agonist that targets the GLP-1r, which we anticipate will enter a Phase 2 clinical trial in early 2016. We have three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
more less
IPO News for vTv Therapeutics
more
IPO Data
IPO File Date 06/15/2015
Offer Price $15.00
Price Range $15.00 - $17.00
Offer Shares (mm) 7.8
Deal Size ($mm) $117
IPO Data
IPO Date 07/29/2015
Offer Price $15.00
Price Range $15.00 - $17.00
Offer Shares (mm) 7.8
Deal Size ($mm) $117
Underwriters
more
Company Data
Headquarters High Point, NC
Founded 1983
Employees 35
Website www.vtvtherapeutics.com